Results 231 to 240 of about 92,728 (309)

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance. [PDF]

Curr Hematol Malig Rep
Al-Abdulmalek A, Landry E, Abdulgayoom M, Al-Mashdali AF, Dalol AA, Muthanna B, Routy JP, Mohamed SF.   +7 more
europepmc   +1 more source

Behind the scenes: how the EMILIN/Multimerin family shapes the cancer landscape

The FEBS Journal, EarlyView.
The EMILIN/Multimerin family members regulate key hallmarks of cancer—including apoptosis, angiogenesis, metastasis, and tumor microenvironment remodeling. As indicated, their function in immune evasion, drug resistance, and metabolic reprogramming remains largely unexplored.
Evelina Poletto, Naike Casagrande, Emanuele Di Siena, Greta Carobolante, Lucrezia Camicia, Giorgia Schinello, Samanta Muzzin, Enrica Timis, Paola Spessotto, Maurizio Mongiat   +9 more
wiley   +1 more source

Rod-Like Cytoplasmic Inclusions in the Peripheral Blood Smear of a Patient with Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Prasad A, Nguyen TB, Carrillo LF.
europepmc   +1 more source

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

The FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma, Mark T. S. Williams   +1 more
wiley   +1 more source

Intravenous Immunoglobulin Reduces Infections for Patients with Chronic Lymphocytic Leukemia: A Single-Center Retrospective Analysis. [PDF]

Cancer Res Commun
Shah NN, Patel T, Kipps TJ, Choi MY.
europepmc   +1 more source

Chronic lymphocytic leukemia.

Experimental oncology, 2013
openaire   +2 more sources

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source

First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs. [PDF]

Clinicoecon Outcomes Res
Perrone V, Innao V, Mazzoni S, Cappuccilli M, Andretta M, Bartolini F, Chinellato A, Dell'Orco S, Ferrante F, Lombardi R, Pagliaro R, Ubertazzo L, Valpondi P, Degli Esposti L.   +13 more
europepmc   +1 more source

Dual IRE1 targets: Determinants of the cell fate?

The FEBS Journal, EarlyView.
IRE1 is an ER stress sensor that restores protein homeostasis through two signaling activities: XBP1s, which upregulates its target gene expression or RIDD which downregulates its target transcripts. We recently identified Dual IRE1 Targets (DIT) which are modulated by both XBP1s and RIDD activities.
Eva Billat, Léane Legrand, Tony Avril, Elodie Lafont   +3 more
wiley   +1 more source

Leveraging a spectrum of cytogenomics methods for profiling complex karyotypes in chronic lymphocytic leukemia. [PDF]

Hum Genomics
Cernovska K, Penazova S, Stranska K, Porc JP, Skalakova P, Ondrouskova E, Rausch T, Svaton J, Tausova K, Kazdova N, Pal K, Hynst J, Benes V, Jarosova M, Pospisilova S, Kotaskova J, Plevova K.   +16 more
europepmc   +1 more source